The diagnosis of allergic diseases is based on a combination of clinical history, physical examination, in vivo challenges, and in vitro test methods for the detection of allergen-specific IgE antibodies in the serum of patients. In spite of the fact that the determination of allergen-specific IgE in serum is widely used in daily clinical practice, one should be aware that such determinations, although useful for routine screening of possible allergies, are not sufficient to diagnose the disease. Clinical history and provocation tests should always be considered to confirm an allergy indicated by elevated allergen-specific IgE levels in serum. This specially applies to the diagnosis of mould allergy in general, and of Aspergillus fumigatusrelated allergic complications in particular.
Introduction
The first documented clinical history of an allergy was reported by Dr. John Bostock which recorded his own case history as first complete description of catarrus aestivus or hay fever in 1819 [1] , followed by the description of pollen grains as causative agents for allergic reactions by Charles Blackley in 1873 [2] . The term "allergy" is derived from the Greek words allos (other) and ergon (reaction) and was proposed by the Viennese paediatrician Clemens von Pirquet in 1906. He described allergy as "an altered capacity of the body to react to a foreign substance" [3] . In 1921 Prausnitz and Küstner discovered a transferable tissue-sensitising factor in serum [4] , which was then identified as a self-protein representing a new immunoglobulin subclass (immunoglobulin E or IgE) by Johansen and Bennich [5] and Ishizaka et al. in 1967 [6] . The pivotal discovery of IgE as a mediator of allergic disease marks the beginning of modern allergology.
Like other immunoglobulins, IgE consists of two light and two heavy chains (ε-isotype) and can be produced in two forms by alternative splicing: a secreted and a membrane-bound form [7] . In sensitised atopic individuals, allergen exposure induces cross-linking of high-affinity Fc RI receptor-bound IgE on effector cells and, thus, immediate release of anaphylactogenic mediators [8] . Normally, IgE is a tissue-bound molecule which is, however, also present in low concentration in serum, in equilibrium with that bound to effector cells [9] . The soluble form of human IgE consists of two identical light chains (either kappa or lambda) that are indistinguishable from the light chains of the other human immunoglobulins. In contrast, the two heavy -chains contain a variable domain (VH) and four isotypespecific structural domains (C 1, C 2, C 3, and C 4) [10] . The structural differences between the IgE constant domains and the constant domains of all other immunoglobulin classes, allows the development of highly specific tests for the detection of serum IgE.
Assays for the In Vitro Determination of Specific IgE Antibodies
The prototype for the in vitro measurement of the serum IgE concentration was the radioallergosorbent test (RAST), first described in 1967 [11] . The original RAST employed a paper disc as solid phase to covalently immobilize the allergen (allergosorbent), used to capture allergen-specific antibodies of all isotypes (mainly IgG, IgA, and IgE) from serum samples. Following different washing procedures to remove unbound serum proteins and antibodies, bound IgE was detected with 125 I-labelled polyclonal anti-human IgE. Results were reported in classes or in arbitrary units (PRU/ml) by interpolation from a reference standard curve [12] .
Although not quantitative, the so-called Phadebas-RAST commercially introduced in 1974 by Pharmacia (Uppsala, Sweden) under the trademark "RAST", represented a milestone for the laboratory diagnosis of atopy. Whilst the terms "RAST" and "RAST class" are still widely used in clinical practice to refer to the presence of allergen-specific IgE in serum, the original radioallergosorbent test has been made obsolete by advances in assay technology. Modern immunoassays for the detection of allergen-specific IgE have undergone relevant improvements, including substitution of the radio-labelled polyclonal antibodies with enzyme-labelled monoclonal detection antibodies [13] , the development of solid phase systems with higher allergen binding capacities [14] , and the introduction of fully automated devices [15] . Most of the currently used IgE detection systems are calibrated against the World Health Organization (WHO) Standard 72/502, and can be considered "quantitative" assays [12] . Results of quantitative assays are expressed in U A or kU A /l where 1 U A IgE antibody corresponds to 1 IU IgE directly convertible to 2.42 ng of IgE [16] . However, the quantity of allergenspecific IgE measured in serum depends on many factors, especially from the quality of the extract immobilised to the solid phase (see below), and might be subject to huge variations between different test systems.
Problems Related to Allergen Extracts and Mould Extracts in Particular
Allergen extracts prepared from natural sources are complex mixtures containing allergenic and non-allergenic proteins. In the normal case the single allergens will constitute a minor component of the extract compared to the non allergenic proteins, because only a minority of the proteins are able to induce a switch to IgE production [17] . These extracts are subject to batch-to-batch variation due to different reasons like extraction procedure used, biochemical stability of the allergens, protease content, and storage [18] . Many efforts have been undertaken to standardize allergen extracts [19] but only a few allergen extract preparations, out of hundreds commercially available, have been approved by the WHO for the use as international standards [20] . Recently, the WHO-IUIS Allergen Standardization Committee has taken an initiative, founded by the European Union, to develop certified reference materials based on purified natural and recombinant allergens [21] . The aim of the project is to develop certified reference materials to be used to standardize allergen extracts. Such material would definitively help to calibrate the internal reference preparations used in different laboratories of manufacturers, research groups, and control authorities against a commonly accepted reference extract. Special problems have been encountered in the standardisation of fungal extracts. The raw material used to prepare fungal extracts derives from fungal cultures grown in complex media. Depending on strain used, culture conditions and time, huge variations in the allergenic potency between different commercial products have been detected [22, 23] . The problem is best exemplified by a study which analysed different commercial fungal extract for their major allergen content using highly specific monoclonal antibodies [24] . The concentration of the major allergen Alt a 1 in Alternaria alternata extracts from 8 companies ranged from less than 0.01 to 6.09 μg/ml. A. fumigatus extracts showed even a much greater variability in the concentration of the major allergen Asp f1 within extracts from 8 companies ranging R. Crameri from less than 0.1 to 64 μg/ml. Obviously serologic and skin test investigations with different extracts showing such a high variability even for the content of major allergens will automatically generate discordant results. This was impressively shown by a skin prick test study with four different commercial A. fumigatus extracts [25] . None of the four commercial skin prick test extracts was able to detect all of the 31 A. fumigatus-sensitised patients enrolled in the study.
Amongst the systems routinely used in the daily clinical practice, ImmunoCAP is considered the "golden standard" for the in vitro determination of IgE [15] . Unfortunately the extracts immobilised on ImmunoCAPs are not available as skin test solution, hampering a direct correlation between in vitro and in vivo diagnostic outcomes.
The most common systems routinely used for the determination of allergenspecific IgE are the already mentioned ImmunoCAP system (Phadia, Uppsala, Sweden), Immulite (DPC Los Angeles, USA), and ADVIA Centaur (Bayer Healthcare, Tarrytwon, NY, USA). Comparative studies of the performance of these systems have been reported and partly correlated with skin test outcomes [26] [27] [28] . Considering the clinical diagnosis of allergy as reference, sensitivity and specificity of all in vitro IgE determination systems give comparable results. However both, sensitivity and specificity varies between allergen extracts tested in all systems. Notably, mould extract panels show identical sensitivity problems (>40%) for all IgE assay systems [28] . The discrepant results between skin test, clinical history, and mould-specific IgE is mainly due to the quality of the mould extracts used provided by different manufacturers [29] .
Clinical Relevance of Serum IgE
Despite the fact that allergen-specific IgE immunoassays are promoted as tests for "allergy diagnosis", the only information provided by the tests relates to the presence or absence of allergen-specific IgE in serum. It is commonly agreed that the presence of allergen-specific IgE is a prerequisite to develop allergic symptoms against a given environmental allergenic source. However, up to more than 40% of the subject with serum IgE to inhalant allergens did not present (respiratory) symptoms [30, 31] and therefore the in vitro determination of allergen-specific IgE is not sufficient for a clinical diagnosis of allergy. The most reliable criterion for a clear diagnosis of an allergy is still a clear correlation between exposure and symptoms that can be derived, in many cases, from the clinical history. Obviously, the patient has to provide the information to the clinician. This might be a relatively simple story in the case of seasonal allergy like hay fewer, or exposure to animal dander. The situation is not so easy in the case of mould allergy where the patient might or might not be aware of the fact that he is exposed to fungal allergens and therefore unable to provide useful information to the clinician.
Although the synthesis of allergen-specific IgE is required for the development of allergic diseases we should not forget that the biologically active form of IgE is not those present as soluble IgE in serum. Whether the presence of allergen-specific IgE translates into clinical allergy depends on a complex interplay of multiple factors recently reviewed [31] . As stated in this review, there are many unanswered important questions that need to be addressed in order to better understand how IgE sensitisation translates into clinical allergy.
Conclusions
Whilst a clinical history is sufficient to identify causes and judge the severity of most allergic diseases, sometimes the history is complex and, especially in polysensitised patients many allergens may be involved. To identify the causative allergens, assessments can be performed in vivo by skin tests or in vitro by measuring allergen-specific serum IgE. Both methods strongly depend from the quality of the extracts used and in this regard recombinant allergens can contribute to substantially improve the diagnostic outcomes [32] . Compared to in vivo tests, in vitro determination of allergen-specific IgE has the advantage to avoid allergen challenges which might elicit severe side effects or even induce a de novo sensitisation. Modern methods for the determination of serum IgE are reliable, reproducible, and quantitative. They represent useful and suitable methods to screen large numbers of patients for potential allergies in clinical routine assessments. However, one should be aware of the fact that, although propagated as methods for "allergy diagnosis", serum IgE-detection systems does not provide a direct evidence for an allergy which always needs to be confirmed by clinical history, skin and/ or provocation tests.
